Details : In a live webcast, Cerevel will lead an in-depth discussion of darigabat, formerly CVL-865, its Phase 2 GABA positive allosteric modulator (PAM) and provide an overview of the PDE4B inhibitor and kappa opioid receptor (KOR) agonist preclinical programs.
Product Name : CVL-865
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 28, 2021
Cerevel Therapeutics Dosed First Patient in Phase 2 Trial of CVL-865 for the Treatment of Epilepsy
Details : The randomized, double-blind, placebo-controlled, parallel group Phase 2 study will assess the efficacy, safety and tolerability profile of CVL-865 as an adjunctive treatment in patients with drug-resistant focal onset seizures.
Product Name : CVL-865
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2020
Reset All
